- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01248780
Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
August 12, 2013 updated by: Centocor, Inc.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
The purpose of this study is to evaluate the safety and efficacy of golimumab in Chinese patients with rheumatoid arthritis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Golimumab is a type of tumor necrosis factor (TNF)-inhibitor.
TNF is a naturally occurring substance in the body, and this substance may cause long-term inflammation.
Golimumab may help fight disease by blocking the activity of TNF in the body and reducing inflammation and pain.
Each patient who is allowed to join the study will be put into a group randomly, like flipping a coin.
Patients may get either golimumab or placebo (which looks like the drug being studied but has no active ingredients, for example a sugar pill).
The chance that the patient will get golimumab is 1 to 1, a 50% chance to receive golimumab and a 50% chance to receive placebo.
If the patient does not have an improvement in their joints at the Week 16 visit compared to when they entered the study, and are in Group 1 (placebo group), the patient will receive golimumab 50 mg every 4 weeks starting at Week 16.
If the patient is in Group 2 (golimumab 50 mg), the patient will continue to receive golimumab every 4 weeks starting at Week 16.
If the patient is in Group 1 and is still receiving placebo injections, because there was improvement in their joints at Week 16, the patient will receive golimumab 50 mg every 4 weeks starting from Week 24.
If the patient is in Group 2 (golimumab 50 mg) or is already receiving golimumab injections at week 24, the patient will continue to receive golimumab every 4 weeks.
Safety will be monitored throughout the study, including drawing blood and looking at laboratory tests, vital signs (e.g., blood pressure), and the frequency and type of adverse events (side effects).
The patient will be in the study approximately 56 weeks.
Patients will receive placebo or active compound (golimumab 50 mg subcutaneous injections) every four weeks from randomization (Week 0) until Week 48.
Study Type
Interventional
Enrollment (Actual)
264
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
-
Chengdu, China
-
Hefei, China
-
Jinan, China
-
Nanjing, China
-
Shanghai, China
-
Suzhou, China
-
Wuhan, China
-
Xi'An, China
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of rheumatoid arthritis for at least 6 months
- Be on a stable dose of methotrexate for 4 weeks
- Have at least 4 swollen and 4 tender joints
Exclusion Criteria:
- Prior exposure to biologic anti-TNFalpha agents
- Inflammatory diseases other than rheumatoid arthritis
- Treatment with Disease Modifying Anti-rheumatic drug (DMARDs)/systemic immunosuppressives other than methotrexate during the 4 weeks prior to the first administration of study agent
- History of, or ongoing, chronic or recurrent infectious disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Golimumab + methotrexate (MTX)
Participants will receive golimumab 50 mg as subcutaneous (SC) (under the skin) injections administered every 4 weeks for up to 48 weeks.
In addition, participants will receive a stable dose of MTX.
|
50 mg subcutaneous (SC) injection every 4 weeks for up to 48 weeks
A stable dose of MTX (oral or injectable) will be administered to participants according to the local prescribing guidelines for up to 48 weeks.
|
EXPERIMENTAL: Placebo + methotrexate (MTX)
Participants will be administered Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48.
In addition, participants will receive a stable dose of MTX.
|
A stable dose of MTX (oral or injectable) will be administered to participants according to the local prescribing guidelines for up to 48 weeks.
Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter up to Week 48.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
American College of Rheumatology (ACR) 20 Response, Using CRP (C-reactive Protein), at Week 14
Time Frame: Week 14
|
ACR 20 response is defined as >= 20% improvement in rheumatoid arthritis (RA) symptoms and disease activity.
|
Week 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Activity Index Score (DAS 28) Response, Using CRP (C-reactive Protein)
Time Frame: Week 14
|
DAS28 using CRP is a measure of tender and swollen joints (28 joints each) and the patient's assessments of disease activity.
A score of higher than 5.1 indicates high disease activity, and a score below 3.2 indicates low disease activity.
A DAS28 (using CRP) responder is defined as a participant with a DAS28 response of "Good" or "Moderate" at Week 14.
A "Good" response is defined as a patient with a DAS28 score of <= 3.2 at Week 14 with improvement from Baseline in DAS28 score of > 1.2.
A "Moderate" response was defined as a patient with DAS28 score of >3.2-5.1 at Week 14 with improvement from baseline in DAS28 score of >0.6 to >1.2
The table below shows the number of participants in each treatment group who were DAS28 responders at Week 14.
|
Week 14
|
American College of Rheumatology 20 Response, Using CRP, at Week 24
Time Frame: Week 24
|
ACR 20 response is defined as >= 20% improvement in rheumatoid arthritis (RA) symptoms and disease activity.
|
Week 24
|
HAQ (Disability Index of the Health Assessment Questionnaire) Score Change From Baseline
Time Frame: Baseline to Week 24
|
The HAQ assesses the degree of difficulty a person has in accomplishing tasks in 8 categories (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living).
The full range of the HAQ scale is 0-24 with 0 being the best possible outcome.
The HAQ score is calculated as the sum of the category scores divided by the number of categories scored, giving a possible range of scores from 0 to 3 with 0 being the best possible outcome (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, or 3=unable to do).
The mean change from baseline at Week 24 in HAQ score is provided below for each treatment group.
A negative change from baseline is indicative of a lesser degree of difficulty in accomplishing tasks assessed in the HAQ.
|
Baseline to Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2010
Primary Completion (ACTUAL)
October 1, 2011
Study Completion (ACTUAL)
July 1, 2012
Study Registration Dates
First Submitted
November 24, 2010
First Submitted That Met QC Criteria
November 24, 2010
First Posted (ESTIMATE)
November 25, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
September 6, 2013
Last Update Submitted That Met QC Criteria
August 12, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Rheumatoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Tumor Necrosis Factor Inhibitors
- Methotrexate
- Golimumab
Other Study ID Numbers
- CR015913
- C0524T28 (OTHER: Centocor)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
Clinical Trials on Golimumab
-
Janssen Research & Development, LLCMerck Sharp & Dohme LLCCompletedColitis, UlcerativeUnited States, France, Poland, Ukraine, Germany, Belgium, Israel, Bulgaria, India, Romania, Serbia, South Africa, Japan, Canada, Australia, Netherlands, New Zealand, Russian Federation, Czech Republic, Hungary, Austria, Denmark, Lit... and more
-
Janssen Research & Development, LLCMerck Sharp & Dohme LLCCompletedColitis, UlcerativeUnited States, Canada, France, Poland, Ukraine, Germany, Israel, Bulgaria, India, Romania, Serbia, South Africa, Japan, Australia, Netherlands, Sweden, Belgium, New Zealand, Russian Federation, Czech Republic, Hungary, Austria, Denmark and more
-
Centocor, Inc.Schering-PloughCompletedArthritis, PsoriaticUnited States, Poland, United Kingdom, Spain, Canada, Belgium
-
Centocor, Inc.Schering-PloughCompletedSpondylitis, AnkylosingUnited States, Germany, Finland, Taiwan, Korea, Republic of, Canada, Belgium, Netherlands, France
-
Hospital de ManisesMerck Sharp & Dohme LLC; Hospital Arnau de Vilanova; Hospital Universitario La... and other collaboratorsUnknown
-
Alvotech Swiss AGActive, not recruitingRheumatoid ArthritisBulgaria
-
Centocor, Inc.Schering-PloughCompletedArthritis, RheumatoidUnited States, Australia, United Kingdom, Germany, Spain, Canada, Finland, Austria, New Zealand, Netherlands
-
Janssen Research & Development, LLCMerck Sharp & Dohme LLCTerminatedColitis, UlcerativeUnited States, Poland, Germany, France, India, Romania, Serbia, Ukraine, Israel, Canada, Netherlands, Sweden, New Zealand, Russian Federation, Australia, Belgium, Hungary, Bulgaria, Slovakia, Latvia, Lithuania, Austria
-
Centocor, Inc.CompletedHealthy VolunteersUnited States
-
Merck Sharp & Dohme LLCCompleted